436 related articles for article (PubMed ID: 28388542)
1. Emerging proteomics biomarkers and prostate cancer burden in Africa.
Adeola HA; Blackburn JM; Rebbeck TR; Zerbini LF
Oncotarget; 2017 Jun; 8(23):37991-38007. PubMed ID: 28388542
[TBL] [Abstract][Full Text] [Related]
2. Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.
Fredolini C; Liotta LA; Petricoin EF
Crit Rev Clin Lab Sci; 2010; 47(3):125-38. PubMed ID: 20858067
[TBL] [Abstract][Full Text] [Related]
3. Proteomics in prostate cancer biomarker discovery.
Larkin SE; Zeidan B; Taylor MG; Bickers B; Al-Ruwaili J; Aukim-Hastie C; Townsend PA
Expert Rev Proteomics; 2010 Feb; 7(1):93-102. PubMed ID: 20121479
[TBL] [Abstract][Full Text] [Related]
4. Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort.
Adeola HA; Smith M; Kaestner L; Blackburn JM; Zerbini LF
Oncotarget; 2016 Mar; 7(12):13945-64. PubMed ID: 26885621
[TBL] [Abstract][Full Text] [Related]
5. Toward an integrated pipeline for protein biomarker development.
Drabovich AP; Martínez-Morillo E; Diamandis EP
Biochim Biophys Acta; 2015 Jun; 1854(6):677-86. PubMed ID: 25218201
[TBL] [Abstract][Full Text] [Related]
6. Molecular markers of prostate cancer.
Bradford TJ; Tomlins SA; Wang X; Chinnaiyan AM
Urol Oncol; 2006; 24(6):538-51. PubMed ID: 17138135
[TBL] [Abstract][Full Text] [Related]
7. Global and Targeted Proteomics of Prostate Cancer Cell Secretome: Combination of 2-Dimensional Image-Converted Analysis of Liquid Chromatography and Mass Spectrometry and In Silico Selection Selected Reaction Monitoring Analysis.
Nurdin A; Hoshi Y; Yoneyama T; Miyauchi E; Tachikawa M; Watanabe M; Terasaki T
J Pharm Sci; 2016 Nov; 105(11):3440-3452. PubMed ID: 27665127
[TBL] [Abstract][Full Text] [Related]
8. Targeted and Untargeted Proteomics Approaches in Biomarker Development.
Sobsey CA; Ibrahim S; Richard VR; Gaspar V; Mitsa G; Lacasse V; Zahedi RP; Batist G; Borchers CH
Proteomics; 2020 May; 20(9):e1900029. PubMed ID: 31729135
[TBL] [Abstract][Full Text] [Related]
9. Proteomics discovery of radioresistant cancer biomarkers for radiotherapy.
Chang L; Graham P; Hao J; Bucci J; Malouf D; Gillatt D; Li Y
Cancer Lett; 2015 Dec; 369(2):289-97. PubMed ID: 26427840
[TBL] [Abstract][Full Text] [Related]
10. Mass spectrometry-based proteomic quest for diabetes biomarkers.
Shao S; Guo T; Aebersold R
Biochim Biophys Acta; 2015 Jun; 1854(6):519-27. PubMed ID: 25556002
[TBL] [Abstract][Full Text] [Related]
11. Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry.
Khoo A; Liu LY; Nyalwidhe JO; Semmes OJ; Vesprini D; Downes MR; Boutros PC; Liu SK; Kislinger T
Nat Rev Urol; 2021 Dec; 18(12):707-724. PubMed ID: 34453155
[TBL] [Abstract][Full Text] [Related]
12. Mass spectrometry-based expression profiling of clinical prostate cancer.
Wright ME; Han DK; Aebersold R
Mol Cell Proteomics; 2005 Apr; 4(4):545-54. PubMed ID: 15695425
[TBL] [Abstract][Full Text] [Related]
13. Systemic sclerosis biomarkers discovered using mass-spectrometry-based proteomics: a systematic review.
Bălănescu P; Lădaru A; Bălănescu E; Băicuş C; Dan GA
Biomarkers; 2014 Aug; 19(5):345-55. PubMed ID: 24831309
[TBL] [Abstract][Full Text] [Related]
14. Proteomics in prostate cancer.
Bañez LL; Srivastava S; Moul JW
Curr Opin Urol; 2005 May; 15(3):151-6. PubMed ID: 15815190
[TBL] [Abstract][Full Text] [Related]
15. Targeted mass spectrometry approaches for protein biomarker verification.
Meng Z; Veenstra TD
J Proteomics; 2011 Nov; 74(12):2650-9. PubMed ID: 21540133
[TBL] [Abstract][Full Text] [Related]
16. Application of proteomic strategies to the identification of urinary biomarkers for prostate cancer: a review.
Downes MR; Byrne JC; Dunn MJ; Fitzpatrick JM; Watson RW; Pennington SR
Biomarkers; 2006; 11(5):406-16. PubMed ID: 16966158
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers of systemic lupus erythematosus identified using mass spectrometry-based proteomics: a systematic review.
Nicolaou O; Kousios A; Hadjisavvas A; Lauwerys B; Sokratous K; Kyriacou K
J Cell Mol Med; 2017 May; 21(5):993-1012. PubMed ID: 27878954
[TBL] [Abstract][Full Text] [Related]
18. Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer.
Kim Y; Jeon J; Mejia S; Yao CQ; Ignatchenko V; Nyalwidhe JO; Gramolini AO; Lance RS; Troyer DA; Drake RR; Boutros PC; Semmes OJ; Kislinger T
Nat Commun; 2016 Jun; 7():11906. PubMed ID: 27350604
[TBL] [Abstract][Full Text] [Related]
19. The role of proteomics in prostate cancer research: biomarker discovery and validation.
Pin E; Fredolini C; Petricoin EF
Clin Biochem; 2013 Apr; 46(6):524-38. PubMed ID: 23266295
[TBL] [Abstract][Full Text] [Related]
20. Cancer biomarker discovery and translation: proteomics and beyond.
Hristova VA; Chan DW
Expert Rev Proteomics; 2019 Feb; 16(2):93-103. PubMed ID: 30556752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
